Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

Recruiting

Phase 1

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin LymphomaImmune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

Sponsor:

AIDS Malignancy Consortium

Code:

NCT05077527

Conditions

AIDS-Related Diffuse Large B-cell Lymphoma

AIDS-Related Non-Hodgkin Lymphoma

HIV Infection

Recurrent Diffuse Large B-Cell Lymphoma

Recurrent Grade 3b Follicular Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Axicabtagene Ciloleucel

Cyclophosphamide

Fludarabine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-29. This information was provided to ClinicalTrials.gov by AIDS Malignancy Consortium on 2024-11-08.